Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Ross Stores, Inc. (ROST) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Ross Stores, Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Ross Stores, Inc. trades at $222 (market cap $71.50B). The key difference: Ross Stores, Inc. is the larger of the two by market cap, and Ross Stores, Inc. pays a 0.8% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | ROST | |
|---|---|---|
Market Cap | $39.89B | $71.50B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $240.13 |
52-Week Low | $278.09 | $127.59 |
Enterprise Value | $38.15B | $72.09B |
Dividend Yield | — | 0.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Ross Stores (ROST) trades at $222.88, up 1.02% with strong momentum near recent highs. The stock shows bullish technical signals with consistent earnings beats in recent quarters (Q3 2025-Q1 2026) and robust fundamentals including 38.98% ROE and 9.74% net margin. Revenue growth accelerated to $21.13B in 2025, with analyst consensus strongly favoring Buy ratings (63.83%) and a $259 price target representing 16% upside potential.
Outlook remains positive given strong operational execution and consumer demand, though valuation multiples (P/E 31.13) appear elevated. Key risks include retail sector competition and economic sensitivity. Institutional sentiment supports further gains if earnings momentum continues through Q2 2026 results.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Ross Stores, Inc.
Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →
